News

News Subscription

Jan 07. 2022 / Ad hoc announcement
Strong Cresemba® (isavuconazole) sales by Astellas in the U.S. trigger CHF 15 million sales milestone payment to Basilea
Read more
Download
Jan 06. 2022
Basilea reports on portfolio progress made in 2021
Read more
Download
Dec 21. 2021 / Ad hoc announcement
Basilea receives USD 10 million milestone payment related to approval of antifungal Cresemba® (isavuconazole) in China
Read more
Download
Dec 17. 2021 / Ad hoc announcement
Basilea announces FDA approval of Investigational New Drug application for novel oncology drug candidate BAL0891
Read more
Download
Dec 08. 2021 / Ad hoc announcement
Continued strong Cresemba® (isavuconazole) sales by Pfizer trigger USD 10 million sales milestone payment to Basilea
Read more
Download
Nov 16. 2021
Basilea announces submission of Investigational New Drug application for novel oncology drug candidate BAL0891
Read more
Download
Oct 11. 2021
Basilea presents preclinical data on synergy between derazantinib and paclitaxel in gastric tumor models at ANE Conference
Read more
Download
Sep 30. 2021 / Ad hoc announcement
Basilea’s partner Asahi Kasei Pharma filed New Drug Application for the marketing authorization of isavuconazole in Japan
Read more
Download
Sep 17. 2021
Basilea presents full safety and efficacy data set on derazantinib in patients with FGFR2 fusion-positive iCCA at ESMO congress
Read more
Download
Aug 17. 2021 / Ad hoc announcement
Basilea reports strong financial results for half-year 2021 with significantly increased cash flow from marketed brands and increases 2021 full-year guidance
Read more
Download